Answers are grounded in this paper and cite their sources.
, and the tumor suppressor p53. In addition, increased understanding of the cellular and molecular constituents of the tumor microenvironment (TME) has created opportunities for further novel therapeutic approaches. New strategies using combination therapies targeting driver mutations and various components of the TME hold promise for improved patient outcomes. This review covers the evolving molecular and therapeutic landscape of cholangiocarcinoma.
No takes yet. Share an insight, caveat, or question.
Khaled W. Kabbara (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: